- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02871310
Vasoactive Effects of IQP-AS-118 in Healthy Individuals
February 10, 2020 updated by: InQpharm Group
Randomized, Double-Blind, Placebo-Controlled, Monocenter, Crossover Investigation to Evaluate the Vasoactive Effects of IQP-AS-118 in Healthy Individuals: A Pilot Study
The main objective of this study is to evaluate the benefit of IQP-AS-118 on the vasoactive effects in healthy subjects.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 10369
- analyze & realize GmbH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Caucasian males and females 45-65 years of age
- Body mass index (BMI) of 25.0-29.9 kg/m2
Blood pressure (BP) at screening:
- systolic blood pressure (SBP) ≤ 140 mmHg or
- diastolic blood pressure (DBP) ≤ 90 mmHg
- EndoPAT score: ≤ 2.00) at screening
- Generally in good health, in particular an electrocardiogram (ECG) without pathological findings at screening
Readiness to comply with study procedures, in particular:
- Consumption of the investigational product (IP) / placebo according to investigator's advise
- Maintaining the same level of physical activity and usual diet during the entire study
- Accepting blood draws
- Able to undergo an EndoPAT assessment
- Complying with visits and all respective requirements for BP and EndoPAT measurements
- Filling in diaries/questionnaires
- Non-smoker since at least 6 months prior to screening and during the study
- Stable body weight in the last 3 months prior to screening (<3 kg self-reported change) and during the study
- Concomitant medications must have been stable at least during the last 1 month prior to screening, if applicable
- In women: postmenopausal for at least 12 months Participation is based upon written informed consent form (ICF) by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study.
Exclusion Criteria:
- Known sensitivity to any components of the IP
- Known primary or secondary hypertension or white-coat hypertension
- Known impaired endothelial function as per investigator's judgement
- Clinically significant disturbances in lipid metabolism e.g. known genetic hyperlipidemia
- Known type-1 / type-2-diabetes
- Untreated or non-stabilized thyroid disorder
History and/or presence of clinically significant cardiovascular disease as per investigator's judgement:
- Known congenital heart defects
- Myocardial infarction, heart failure, angina pectoris, life-threatening arrhythmia or stroke within the last 6 months prior to screening
- Existing thrombosis or disposition to thrombosis
Any other known significant or serious condition / disease that renders subjects ineligible, e.g.:
- History of malignancy within ≤5 years prior to screening
- Bleeding disorder and/or need for anticoagulants or anti-platelet agents
- Current psychiatric care and/or use of neuroleptics
- Bariatric surgery in the last 12 months prior to screening
- Any known metabolic disease, gastrointestinal disorder or other clinically significant disease/disorder which in the investigator's opinion could interfere with the results of the study or the safety of the subject
- Known arm lymphedema (e.g. due to mastectomy)
- Other clinically relevant excursions of safety parameters or any other clinically significant abnormality in hematology and/or biochemistry at the Investigator's judgement
- Dietary habits and/or restrictions that may affect the study outcome
- Eating disorder or participation in a weight loss program
- Use of medications (e.g. statins, renin angiotensin system inhibitors, nevibolol, carvedilol, calcium channel blockers) or supplements that can influence vascular endothelial function and/or blood flow (e.g. garlic, cocoa) within the last 4 weeks prior to screening and during the study
- Use of antiplatelet agents and / or anticoagulants (e.g. warfarin, acetylsalicylic acid) within the last 4 weeks prior to screening and during the study
- Use of medications or supplements that can influence SBP or DBP (e.g. ACE inhibitors, diuretics, calcium channel, α- or ß-blockers, grape seed extract, coenzyme Q10 etc.) within the last 4 weeks prior to screening and during the study
- Use of lipid lowering medications (affecting lipid metabolism, platelet function or antioxidant status, etc.) and/or dietary supplements (e.g. omega-3 fatty acids, green tea extract, calcium, red yeast rice, phytosterols (incl. enriched products such as e.g. Becel), niacin,, glucomannan or chitosan ) within the last 4 weeks prior to screening and during the study
- Use of medications that can influence cholesterol levels significantly (e.g. corticosteroids, amiodarone, estrogen, anabolic steroids) according to investigator's judgement
- Use of weight loss treatment
- Alcohol abuse (men: ≥21 units/week, women: ≥14 units/ week; 1 unit equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
- Drug abuse
- Reported participation in night shift work 2 weeks prior to screening and/or during the study
- Participation in another study or blood donation during the last 30 days prior to screening and during the study
- Any other reason deemed suitable for exclusion per investigator's judgment, e.g. insufficient compliance with study procedures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IQP-AS-118
To be taken once daily dosing of 1 tablet in the morning with 250 mL of water.
The tablets should not be chewed, but swallowed whole.
|
1 tablet in the morning
|
Placebo Comparator: Placebo
To be taken once daily dosing of 1 tablet in the morning with 250 mL of water.
The tablets should not be chewed, but swallowed whole.
|
1 tablet in the morning
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in EndoPAT (chronic effect)
Time Frame: 12 weeks
|
Pre-dose at the end vs. start of each intervention (week 4 vs. week 0 and week 12 vs.
week 8, respectively) (inclusive of 4 weeks of wash-out period)
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in EndoPAT (acute effect)
Time Frame: 12 weeks
|
3 h post-dose vs. pre-dose at start of each intervention (week 0 and week 8, respectively) (inclusive of 4 weeks of wash-out period)
|
12 weeks
|
Changes in ex vivo blood platelet aggregation / adhesion (acute effect)
Time Frame: 12 weeks
|
3 h post-dose vs. pre-dose at start of each intervention (week 0 and week 8, respectively) (inclusive of 4 weeks of wash-out period)
|
12 weeks
|
Changes in ex vivo blood platelet aggregation / adhesion pre-dose (chronic effect)
Time Frame: 12 weeks
|
End vs. start of each intervention (week 4 vs. week 0 and week 12 vs.
week 8, respectively) (inclusive of 4 weeks of wash-out period)
|
12 weeks
|
Changes in blood coagulation / clotting parameters (acute effect)
Time Frame: 12 weeks
|
3 h post-dose vs. pre-dose at start of each intervention (week 0 and week 8, respectively) (inclusive of 4 weeks of wash-out period)
|
12 weeks
|
Changes in blood coagulation / clotting parameters predose (chronic effect)
Time Frame: 12 weeks
|
End vs. start of each intervention (week 4 vs. week 0 and week 12 vs.
week 8, respectively) (inclusive of 4 weeks of wash-out period)
|
12 weeks
|
Global evaluation of benefit
Time Frame: 12 weeks
|
Assessed by the subjects and investigator at end of each intervention (inclusive of 4 weeks of wash-out period)
|
12 weeks
|
Changes in SF- 12
Time Frame: 12 weeks
|
End vs. start of each intervention (week 4 vs. week 0 and week 12 vs.
week 8, respectively) (inclusive of 4 weeks of wash-out period)
|
12 weeks
|
Physical examination
Time Frame: 12 weeks
|
End of each intervention vs. screening (Week 4 vs. screening, week 12 vs.
screening) (inclusive of 4 weeks of wash-out period)
|
12 weeks
|
Pulse rate
Time Frame: 12 weeks
|
End vs. start of each intervention (Week 4 vs. week 0, week 12 vs.
week 8) (inclusive of 4 weeks of wash-out period)
|
12 weeks
|
Systolic Blood Pressure
Time Frame: 12 weeks
|
End vs. start of each intervention (Week 4 vs. week 0, week 12 vs.
week 8) (inclusive of 4 weeks of wash-out period)
|
12 weeks
|
Diastolic Blood Pressure
Time Frame: 12 weeks
|
End vs. start of each intervention (Week 4 vs. week 0, week 12 vs.
week 8) (inclusive of 4 weeks of wash-out period)
|
12 weeks
|
Assessment of Adverse Events
Time Frame: 12 weeks
|
Start and end of each intervention (Week 0, week 4, week 8 and week 12) (inclusive of 4 weeks of wash-out period)
|
12 weeks
|
Global assessment of tolerability
Time Frame: 12 weeks
|
Assessed by the subjects and investigator (4-point categorical scale) at week 4 and week 12
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ralf Uebelhack, analyze & realize GmbH
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 1, 2018
Primary Completion (Anticipated)
December 1, 2018
Study Completion (Anticipated)
December 1, 2018
Study Registration Dates
First Submitted
August 10, 2016
First Submitted That Met QC Criteria
August 14, 2016
First Posted (Estimate)
August 18, 2016
Study Record Updates
Last Update Posted (Actual)
February 12, 2020
Last Update Submitted That Met QC Criteria
February 10, 2020
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INQ/030815
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
Morehouse School of MedicineNot yet recruiting
-
Yonsei UniversityRecruitingCardiovascular DiseaseKorea, Republic of
-
Nanjing Medical UniversityNot yet recruitingCardiovascular Disease
-
National Human Genome Research Institute (NHGRI)Active, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
AmgenCompletedCardiovascular DiseaseUnited States, Australia
-
VA Office of Research and DevelopmentEnrolling by invitationCardiovascular DiseaseUnited States
Clinical Trials on IQP-AS-118
-
InQpharm GroupCompletedBlood Pressure | Low Density Lipoprotein Cholesterol LevelGermany
-
InQpharm GroupWithdrawn
-
InQpharm GroupCompletedUpper Respiratory Tract SymptomsGermany
-
InQpharm GroupTerminatedCommon Cold | Upper Respiratory Tract InfectionsGermany
-
InQpharm GroupCompleted
-
InQpharm GroupCompleted
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID); ImQuest Pharmaceuticals...Completed
-
InQpharm GroupCompletedAppetite Regulation | Energy Intake | Appetite SuppressionGermany
-
Dow Pharmaceutical SciencesUnknownPlaque PsoriasisUnited States
-
InQpharm GroupCompleted